NPC1L1 and sarcopenia: While our findings offered valuable insights, large-scale and well-designed cohort studies in real-world settings are still imperative to examine the causal effects of long-term use of HMGCR, PCKS9, and NPC1L1 inhibitors on sarcopenia.